Impact Factor
4.53
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
10.39
1,550 total citations
h5-index
51
h5 depth signal
Cited share
92.2%
141 of 153
Total citations
1,550
Citation footprint
Metric signal
9.66
External metric anchor
Self-citation
1.5%
24 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
685
Canada
92
United Kingdom
71
Australia
42
Italy
41
Citing Fields of Research
Oncology
438
Immunology
140
Breast Cancer
112
Lung Cancer
93
Lymphomas
71
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,389
Articles tracked across the journal lifetime
Indexed publication set
153
141 cited publications
Last 12 months
78
15.6 publications/month
Open access share
0.0%
0 OA publications in the last year
Leading citing country
United States
685 citing publications
Leading citing field
Oncology
438 citing publications
Latest tracked publication
1 December 2026
10 recent records available
Coverage & Indexing History
2012-
2012-
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Lung Cancer
Immunology
Palliative Care
Issuing & Sponsoring Bodies
Contributor
American Society of Clinical Oncology. Annual Meeting
Contributor
American Society of Clinical Oncology
Broad Categories
Neoplasms
Palliative Care
Immunology
Urology
Breast Cancer
Hematology
Lung Cancer
Immunotherapy
MeSH Descriptors
Medical Oncology
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1200/edbk-26-00006
Open DOI
Acknowledgment of Reviewers 2026
02
DOI 10.1200/edbk-26-00009
Open DOI
New Tractor
03
DOI 10.1200/edbk-26-00005
Open DOI
Finding Hope, One Breath at a Time
04
DOI 10.1200/edbk-26-00001
Open DOI
Reinventing the ASCO Educational Book to Capture the Advances in Oncology Year-Round
05
DOI 10.1200/edbk-26-519336
Open DOI
Navigating Multimodality Therapy in Non-Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches.
Neoadjuvant and perioperative immunotherapy have redefined the treatment landscape for select patients with early-stage and locally-advanced resectable non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors targeting the PD-1/P...
06
DOI 10.1200/edbk-26-521646
Open DOI
Cancer Care for Immigrant Populations in the United States.
Immigrants comprise a substantial and growing proportion of the US population, yet they face profound barriers to timely, affordable, and high-quality cancer care. These barriers are shaped not only by language, culture, and health liter...
07
DOI 10.1200/edbk-26-520562
Open DOI
Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma
Immunotherapy and BRAF-targeted therapy strategies reduce recurrence risk and improve survival in patients with high-risk resected and metastatic melanoma, respectively. Optimizing the use of these treatment options can maximize clinical...
08
DOI 10.1200/edbk-26-525006
Open DOI
Advances in Systemic Therapies for Rare Head and Neck Malignancies: Spotlight on Adenoid Cystic Carcinoma, Differentiated Thyroid Cancer, and Sinonasal/Paranasal Tumors
Rare head and neck cancers, including adenoid cystic carcinoma (ACC), differentiated thyroid cancer (DTC), and sinonasal/paranasal tumors, represent a diverse pathology with shared clinical challenges, including heterogenous biology and ...
09
DOI 10.1200/edbk-26-518934
Open DOI
Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies
Neuroendocrine neoplasms (NENs) represent a heterogeneous group of malignancies ranging from relatively indolent well-differentiated neuroendocrine tumors (NETs) to more aggressive poorly differentiated neuroendocrine carcinomas (NECs). ...
10
DOI 10.1200/edbk-26-520792
Open DOI
Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications
Immune checkpoint inhibitors (ICIs) have transformed the treatment of a broad range of malignancies over the past decade. As the scope of indications and the clinical experience expands, oncologists are increasingly confronted with compl...
Bibliographical & Catalog Notes
Description based on: 38th (2002).
Latest issue consulted: 40th (2004).
Print issues ceased with 2020?
Also issued online.